American Thoracic Society - Sanofi Investor Call

Key Respiratory development milestones since March 2022 sanofi Immunology Event March 2022 Amlitelimab Initiated Phase 2b study in Asthma Anti-IL-13/TSLP Nanobody® VHH Demonstrated Proof of Mechanism in Phase 1 study in Asthma DupixentⓇ Positive Phase 3 results with dupilumab in COPD (BOREAS study) Itepekimab Granted a Fast Track Designation status by FDA for COPD indication in January 2023 Dupixent® is jointly developed and co-commercialized with Regeneron. Itepekimab is being developed in collaboration with Regeneron. 6 ATS Investor Call Itepekimab Positive interim analysis in COPD (AERIFY 1 & 2 studies) sanofi ATS 2023 Today

View entire presentation